Basal Insulin for Type 2 Diabetes Patients Treated in Outpatient Clalit Clinics (Lapas II)
Type 2 Diabetes
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Lantus for Diabetic Patients Treated in Clalit Outpatient Clinics|
- Decrease in HbA1c level [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Safety measures [ Time Frame: 7 months ] [ Designated as safety issue: No ]
|Study Start Date:||August 2008|
|Study Completion Date:||January 2012|
|Primary Completion Date:||January 2012 (Final data collection date for primary outcome measure)|
Patients with diabetes treated in outpatient clinics will be recruited by their primary care physician. Recruitment period will be 3 months per center and each patient will be followed for 7 months Diabetes specialists will be responsible for 50-65 primary care physicians. The specialists will advise and direct the primary care physician through the whole study period.
The study protocol includes patients treated with different types of non short- acting insulin. Insulin Lantus (including dose) will be started by the primary physician, if needed after consulting the Diabetes Specialist. The treatment should follow the study protocol.
Patients will have 3 pre-scheduled visits in their clinic: 1. At the beginning of study. 2. After 3 months. 3. At study end (after 6 month). An additional telephone contact will take place 1 month after last visit. to evaluate adherence to therapy Data collecting: Data including HbA1c, FPG,current diabetic treatment, dose of insulin Lantus, and relevant additional diseases\complaints will be collected at each visit. Additional information as demographic data, medical history will be collected at beginning of study.
Safety: Hypoglycaemic episodes will be recorded
Please refer to this study by its ClinicalTrials.gov identifier: NCT00726674
|Sanofi-Aventis Administrative Office|
|Study Director:||Nurit Tweezer-Zaks||Sanofi|